Defining Models to Classify Between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804981

Authors

Elisabeth Reiser

Dietmar Pils

Christoph Grimm

Ines Hoffmann

Stephan Polterauer

Marlene Kranawetter

Stefanie Aust

Affiliations

Soon will be listed here.

Abstract

Discrimination between benign and malignant adnexal masses is essential for optimal treatment planning, but still remains challenging in a routine clinical setting. In this retrospective study, we aimed to compare albumin as a single parameter to calculate models by analyzing laboratory parameters of 1552 patients with an adnexal mass (epithelial ovarian cancer (EOC): = 294; borderline tumor of the ovary (BTO): = 66; benign adnexal mass: = 1192) undergoing surgery. Models comprising classical laboratory parameters show better accuracies (AUCs 0.92-0.93; 95% CI 0.90-0.95) compared to the use of single markers, and could easily be implemented in clinical practice by containing only readily available markers. This has been incorporated into a nomogram.

Citing Articles

Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.

Zhang D, Xu R, Huo T, Liu Y, Hao Z, Sun Y BMC Womens Health. 2024; 24(1):274.

PMID: 38704534 PMC: 11069129. DOI: 10.1186/s12905-024-03117-9.

Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors.

Dabi Y, Favier A, Razakamanantsoa L, Delbos L, Poilblanc M, Descamps P Cancers (Basel). 2023; 15(5).

PMID: 36900328 PMC: 10001105. DOI: 10.3390/cancers15051539.

References

Reiser E, Aust S, Seebacher V, Reinthaller A, von Mersi H, Schwameis R . Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass. Eur J Obstet Gynecol Reprod Biol. 2019; 239:16-20. DOI: 10.1016/j.ejogrb.2019.05.031. View

Bastani A, Asghary A, Heidari M, Karimi-Busheri F . Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients. Eur J Gynaecol Oncol. 2018; 38(3):418-424. View

Dunton C, Hutchcraft M, Bullock R, Northrop L, Ueland F . Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. Diagnostics (Basel). 2021; 11(8). PMC: 8394730. DOI: 10.3390/diagnostics11081440. View

Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D . Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer. 2016; 26(9):1586-1593. DOI: 10.1097/IGC.0000000000000804. View

Marnell L, Mold C, Du Clos T . C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117(2):104-11. DOI: 10.1016/j.clim.2005.08.004. View

Winarto H, Laihad B, Nuranna L . Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2014; 15(5):1949-53. DOI: 10.7314/apjcp.2014.15.5.1949. View

Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L . The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2013; 171(1):101-6. DOI: 10.1016/j.ejogrb.2013.07.044. View

Timmerman D, Planchamp F, Bourne T, Landolfo C, Bois A, Chiva L . ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. Facts Views Vis Obgyn. 2021; 13(2):107-130. PMC: 8291986. DOI: 10.52054/FVVO.13.2.016. View

Al Musalhi K, Al Kindi M, Al Aisary F, Ramadhan F, Al Rawahi T, Al Hatali K . Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Med J. 2016; 31(5):336-44. PMC: 4996955. DOI: 10.5001/omj.2016.68. View

10.

Choi H, Lee Y, Sohn I, Kim Y, Kim J, Kang S . Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study. Curr Probl Cancer. 2019; 44(2):100508. DOI: 10.1016/j.currproblcancer.2019.100508. View

11.

Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A . Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Arch Gynecol Obstet. 2019; 300(4):1015-1022. PMC: 6759670. DOI: 10.1007/s00404-019-05278-7. View

12.

Bennette C, Vickers A . Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol. 2012; 12:21. PMC: 3353173. DOI: 10.1186/1471-2288-12-21. View

13.

Minar L, Felsinger M, cermakova Z, Zlamal F, Bienertova-Vasku J . Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors. Int J Gynaecol Obstet. 2017; 140(2):241-246. DOI: 10.1002/ijgo.12371. View

14.

Karlsen M, Hogdall E, Christensen I, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L . A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass. Gynecol Oncol. 2015; 138(3):640-6. DOI: 10.1016/j.ygyno.2015.06.021. View

15.

Reiser E, Aust S, Seebacher V, Reinthaller A, Helmy-Bader S, Schwameis R . Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses. Gynecol Oncol. 2017; 147(3):690-694. DOI: 10.1016/j.ygyno.2017.09.018. View

16.

Timmerman D, Van Calster B, Testa A, Guerriero S, Fischerova D, Lissoni A . Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010; 36(2):226-34. DOI: 10.1002/uog.7636. View

17.

Carreras-Dieguez N, Glickman A, Munmany M, Casanovas G, Agusti N, Diaz-Feijoo B . Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. Diagnostics (Basel). 2022; 12(1). PMC: 8774736. DOI: 10.3390/diagnostics12010226. View

18.

Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa A . Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019; 20(3):448-458. DOI: 10.1016/S1470-2045(18)30837-4. View

19.

Gatta A, Verardo A, Bolognesi M . Hypoalbuminemia. Intern Emerg Med. 2012; 7 Suppl 3:S193-9. DOI: 10.1007/s11739-012-0802-0. View

20.

Sevinc A, Adli M, Kalender M, Camci C . Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007; 8(12):1054-1055. DOI: 10.1016/S1470-2045(07)70357-1. View